Japan moves to protect drug innovators
Originator pharmaceutical companies are facing growing pressures from generic rivals in Japan. But, as Makoto Ono of Anderson Mori & Tomotsune explains, they are gaining support from the JPO and the country’s courts
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
